Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Advanced Solid Tumour

Stomach Neoplasms

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Advanced Solid Tumour

HER2-positive Gastric Cancer

HER2-positive Breast Cancer

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Adenocarcinoma

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Adenocarcinoma, Neoplasms

Resectable Colon Cancer

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Advanced Solid Tumors

Breast Neoplasms, Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Advanced Solid Tumor Cancer

Breast Neoplasms

Breast Neoplasms

Pancreatic Ductal Adenocarcinoma

Stomach Neoplasms

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Metastatic HER2-positive Breast Cancer

HER2-low Breast Cancer

Stomach Neoplasms

Nasopharyngeal Carcinoma, Recurrence

Gastrointestinal Neoplasms

Advanced Cancer

Colonic Neoplasms

Advanced Solid Tumors

Clinical Trials

Pan Tumor Rollover Study

NeoB-Cap1

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

MK-3475-06C

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

MK-2870-010

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

DG-03

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

BREnnA

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

LUCERNA

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

ASPEN-09-03

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

PARC

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Morpheus-panBC

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Magic-C002

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors